Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
| Brand name | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE |
| Generic name | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM |
| Distributed by / for | Macleods Pharma Usa Inc |
| NDC | 33342-052-07 |
| Full product label | Losartan potassium & Hydrochlorothiazide Tablets 100 mg/25 mg, 30, 90 & 1000 count NDC # 33342-052-07, NDC #33342-052-10 & NDC # 33342-052-44, Rx Only, MFR: Macleods Pharma USA, Inc. Plainsboro, NJ 08536 |
| Recalling firm | Macleods Pharma Usa Inc |
| Distribution | Product was distributed nationwide. |
| Quantity | 84/1000 count bottles |
| Recall initiated | 2022-06-10 |
| Report date | 2022-07-06 |
| Recall completed | 2024-05-23 |
| Recall number | D-1164-2022 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Plainsboro NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗